Batirel, AyşeBalkan, İlker İnançKarabay, OğuzAğalar, CananAkalın, ŞerifeAlıcı, ÖzlemAlp, EmineAltay, Fatma AybalaAltın, NilgünArslan, FerhatAslan, TuranBekiroğlu, NurayCesur, SalimÇelik, Aygül DoganDoğan, MustafaDurdu, BülentDuygu, FaziletEngin, AynurEngin, Derya ÖztürkGönen, İbakGüçlü, ErtuğrulGüven, TümerHatipoğlu, Çiğdem AtamanHoşoğlu, SalihKarahocagil, Mustafa KasımUlu Kılıç, AysegülÖrmen, BaharÖzdemir, DavutÖzer, SerdarÖztoprak, NefiseSezak, NurbanuTurhan, VedatTürker, NesrinYılmaz, Hava10.07.20192019-07-1010.07.20192019-07-102014Batirel, A., Balkan, İ. İ., Karabay, O., Ağalar, C., Akalın, Ş., Alıcı, Ö. ... Yılmaz, H. (2014). Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases, 33(8), 1311-1322. https://dx.doi.org/10.1007/s10096-014-2070-60934-97231435-4373https://dx.doi.org/10.1007/s10096-014-2070-6https://hdl.handle.net/20.500.12511/240523rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- 41394 -- Berlin, GERMANYWOS: 000338723600006PubMed ID: 24532009The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.eninfo:eu-repo/semantics/openAccessColistin-CarbapenemColistin-SulbactamColistin PlusAntibacterialArticle3381311132210.1007/s10096-014-2070-6Q3Q1